A variety of human diseases are suspected to be directly linked to protein misfolding. Highly organized protein aggregates, called amyloid fibrils, and aggregation intermediates are observed; these are considered to be mediators of cellular toxicity and thus attract a great deal of attention from investigators. Neurodegenerative pathologies such as Alzheimer's disease account for a major part of these protein misfolding diseases. The last decade has witnessed a renaissance of interest in inhibitors of tau aggregation as potential disease-modifying drugs for Alzheimer's disease and other " tauopathies". The recent report of a phase II clinical trial with the tau aggregation inhibitor MTC could hold promise for the validation of the concept. This Review summarizes the available data concerning small-molecule inhibitors of tau aggregation from a medicinal chemistry point of view. © 2009 Wiley-VCH Verlag GmbH & Co. KGaA.
CITATION STYLE
Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E. M., Waldmann, H., & Mandelkow, E. (2009, February 23). Development of tau aggregation inhibitors for alzheimer’s disease. Angewandte Chemie - International Edition. https://doi.org/10.1002/anie.200802621
Mendeley helps you to discover research relevant for your work.